Medical Mythbusting Commentary for February 16, 2021
Reference:Last week the NEJM published a study concluding “In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”
A follow up editorial provides some perspective.